CoChat
Sign Up
Cited by 165Atrial Fibrillation Management and OutcomesCardiac pacing and defibrillation studiesHeart rate and cardiovascular health

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies

Van Gelder, Isabelle C., Wyse, D. George, Chandler, Mary L., Cooper, Howard A., Olshansky, Brian, Hagens, Vincent E., Crijns, Harry J.G.M.·2006·EP Europace
DOI 10.1093/europace/eul106
Open this paper in CoChat — free account

Abstract

AIMS: The AFFIRM and RACE studies showed that rate control is an acceptable treatment strategy for atrial fibrillation (AF). We examined whether strict rate control offers benefit over more lenient rate control. METHODS AND RESULTS: We compared the outcome of patients enrolled in the rate-control arms of AFFIRM and RACE, using data from patients who met a composite of overlapping inclusion and exclusion criteria. We evaluated 1091 patients, 874 from AFFIRM and 217 from RACE. In AFFIRM, the rate-control strategy aimed for a resting heart rate < or =80 bpm and heart rate during daily activity of < or =110 bpm. In RACE, a more lenient approach was taken: resting heart rate <100 bpm. Primary endpoint was a composite of mortality, cardiovascular hospitalization, and myocardial infarction. Mean heart rate across all follow-up visits for patients in AF was lower in AFFIRM (76.1 vs. 83.4 bpm). Event-free survival for the occurrence of the primary endpoint did not differ (64% in AFFIRM vs. 66% in RACE). Patients with mean heart rates during AF within the AFFIRM (< or =80) or RACE (<100) criteria had a better outcome than patients with heart rates > or =100 (hazard ratios 0.69 and 0.58, respectively, for < or =80 and <100 compared with > or =100 bpm). CONCLUSION: Stringency of the approach to rate control, based on the comparison of the AFFIRM and RACE studies, was not associated with an important difference in clinical events.

Overview

Integrity signals

Registry

Crossref · 10.1093/europace/eul106

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

Sorted by citations

Items 101–164 of 164

Related

See all

Metadata

Authors
Van Gelder, I. C., Wyse, D. G., Chandler, M. L., Cooper, H. A., Olshansky, B., Hagens, V. E., & Crijns, H. J. G. M.
Affiliations
  • Libin Cardiovascular Institute of Alberta (CA)
  • MedStar Washington Hospital Center (US)
  • University of Iowa (US)
  • University Medical Center Groningen (NL)
  • Maastricht University Medical Centre (NL)
ORCID
Venue
EP Europace
Publisher
Oxford University Press (OUP)
Published
2006-09-14
Volume
8
Issue
11
Pages
935-942
ISSN
  • 1099-5129 (ISSN-L)
  • 1532-2092
DOI
10.1093/europace/eul106
OpenAlex
W2117915052
Cited by
165
References
17
Citations by year
2026: 3 · 2025: 5 · 2024: 7 · 2023: 12 · 2022: 9 · 2021: 13 · 2020: 12 · 2019: 3 · 2018: 7 · 2017: 13 · 2016: 8 · 2015: 7 · 2014: 6 · 2013: 9 · 2012: 7
FWCI
5.71
Type
journal article
Language
en
Open access
closed
Locations
  • EP Europace (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • National Institutes of Health (n01hc055139-000)
  • National Heart, Lung, and Blood Institute (N01-HC-55139)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
atrial fibrillation, rate control, resting heart rate, target heart rate, event-free survival, mortality, cardiovascular hospitalization, myocardial infarction, AFFIRM trial, pooled analysis
MeSH terms
Aged, Atrial Fibrillation, Cardiac Pacing, Artificial, Clinical Trials as Topic, Female, Heart Rate, Humans, International Cooperation, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Survival Rate, Proportional Hazards Models, Survival Analysis, Treatment Outcome, Outcome Assessment, Health Care, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review